HUMA Humacyte
- 5.480
- +0.780+16.60%
- 5.710
- +0.230+4.20%
Humacyte News
The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioScience
The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioSciences rose 16.60%-10.00% Novocure also rose 9.17%; Zent
10-Q: Quarterly report
Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Rallybio (RLYB)
Benchmark: Reiterates Humacyte (HUMA.US) rating and adjusted from buy to buy rating, target price is $15.00.
Benchmark: Reiterates Humacyte (HUMA.US) rating and adjusted from buy to buy rating, target price is $15.00.
Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.
Humacyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 216.46% Benchmark → $15 Reiterates Buy → Buy 04/01/2024 47.68% Cantor Fitzgerald → $7 Reiterate
Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)
Humacyte Inc (HUMA) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
Humacyte to Participate at Upcoming Investor Conferences in May
PDF Version DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human
Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns With Analyst Projections Amid Strategic Advances
Peering Into Humacyte's Recent Short Interest
Humacyte's (NYSE:HUMA) short percent of float has fallen 13.81% since its last report. The company recently reported that it has 3.94 million shares sold short, which is 4.37% of all regular shares th
Insiders, Hedge Funds, and Politicians Trading Humacyte Stock (NDAQ:HUMA) in Q1 2024
Humacyte Reported Cash and Cash Equivalents of $115.5M as of March 31 >HUMA
Humacyte Reported Cash and Cash Equivalents of $115.5M as of March 31 >HUMA
Humacyte Q1 EPS $(0.29) Misses $(0.23) Estimate, Exits Quarter With Cash & Equivalents Worth $115.5M
Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 19.44 percent increase over losses of $(0.36) p
Humacyte 1Q Loss $31.9M >HUMA
Humacyte 1Q Loss $31.9M >HUMA
Humacyte First Quarter 2024 Financial Results and Business Update
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the first quarter ended March 31, 2024 and highlighted recent accomplishments advancing the investigational Human Acellular Vessel (HAV) closer to planned U.S. market launch.
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
PDF Version DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54
OPI, RVNC and AQST Are Among After Hour Movers
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Super Micro Computer, Inc. (NASDAQ:SMCI) fell sharply during Friday's session.The company announced its third-quarter earnings date and did not provide preliminary estimates as it did with t
Analysis
Price Target
No Data
